Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.63 |
| ▸ | TACR2 | P21452 | 12/20 | 0.63 |
| ▸ | TAC3 | Q9UHF0 | 4/20 | 0.63 |
| ▸ | TACR3 | P29371 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149302 | 1.00 | TACR1 (0.63) | TACR1TACR2TAC3TACR3CYP3A4 | |
| SCHEMBL4149299 | 1.00 | TACR1 (0.63) | TACR1TACR2TAC3TACR3CYP3A4 | |
| SCHEMBL4141397 | 0.94 | TACR1 (0.57) | TACR1TACR2TAC3TACR3CYP3A4 | |
| SCHEMBL4141392 | 0.94 | TACR1 (0.57) | TACR1TACR2TAC3TACR3CYP3A4 | |
| SCHEMBL4159804 | 0.94 | TACR1 (0.57) | TACR1TACR2TAC3TACR3CYP3A4 | |
| SCHEMBL4155097 | 0.93 | TACR1 (0.64) | TACR1TACR2TAC3TACR3 | |
| SCHEMBL4154005 | 0.93 | TACR1 (0.64) | TACR1TACR2TAC3TACR3 | |
| SCHEMBL4155095 | 0.93 | TACR1 (0.64) | TACR1TACR2TAC3TACR3 | |
| SCHEMBL4154010 | 0.93 | TACR1 (0.64) | TACR1TACR2TAC3TACR3 | |
| SCHEMBL4154014 | 0.93 | TACR1 (0.64) | TACR1TACR2TAC3TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | TACR1 9/4885TACR2 19/4885TAC3 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.